Bristol-Myers Squibb Co (NYSE:BMY) traded at $58.74 at close of the session on Tuesday, November 26 and made a downward move of -0.07% on its previous day’s price.
Looking at the stock we see that its previous close was $58.78 and the beta (5Y monthly) reads 0.441 with the day’s price range being $58.06 – $59.08. In terms of its 52-week price range, BMY has a high of $61.08 and a low of $39.35. The company’s stock has gained about 11.59% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bristol-Myers Squibb Co has a market cap of $119.14 billion and is expected to release its quarterly earnings report in December. With its Forward Dividend at 2.40 and a yield of 4.09%, the company’s investors could be anxious for the BMY stock to gain ahead of the earnings release.
On the other hand, looking at the outlook for the BMY stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 14 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 9 have rated the Bristol-Myers Squibb Co (BMY) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 3.25% off its SMA20 and 8.74% from its 50-day simple moving average. The RSI (14) is pointing at 61.91 while the volatility over the past week is 2.25% and jumps to 2.67% over the past one month. The beta value is 0.45, while the average true range (ATR) is currently pointing at 1.62. The average price target for the stock over the next 12 months is $66.5, with the estimates having a low of $41 and a high of $85. These price ends are 30.2% and -44.71% off the current price level respectively, although investors could be excited at the prospect of a -13.21% if the BMY share price touches on the median price of $66.5.
Coming back to Bristol-Myers Squibb Co (NYSE:BMY), we note that the average 3-month trading volume was 11.05 million, while that of the preceding 10-day period stands at 12.32 million. Current shares outstanding are 2.03 billion.
The insiders hold 0.08% of the company’s shares while institutions hold 77.72%. The data shows that short shares as of 2024-11-15, stood at 25.77 million at a short ratio of 2.34. This represents a 127.00 short interest in shares outstanding on 2024-11-15. Shares short rose in November from the previous month at 22.5 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 14.48% up in year-to-date price movement.
